Key terms
About BOLD
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BOLD news
Apr 22
6:40am ET
Analysts’ Opinions Are Mixed on These NA Stocks: Boundless Bio Inc. (BOLD) and Solventum Corporation (SOLV)
Apr 22
6:27am ET
Boundless Bio initiated with an Outperform at Leerink
Apr 22
6:19am ET
Boundless Bio initiated with a Buy at Guggenheim
Apr 22
4:59am ET
Boundless Bio initiated with an Overweight at Piper Sandler
Apr 22
4:41am ET
Boundless Bio intiated with Not Rated at Goldman Sachs
Apr 21
6:24am ET
Opening Day: Ibotta soars in strong market debut
Apr 11
8:06am ET
Boundless Bio doses first patient in BBI-825 trial
Apr 08
8:07am ET
Boundless Bio presents preclinical data on BBI-355
No recent press releases are available for BOLD
BOLD Financials
Key terms
Ad Feedback
BOLD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BOLD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range